Chinese CRISPR company YolTech raises $45M as it plans for first Phase 3 study

YolTech Therapeutics, a prolific Chinese biotech that’s already begun testing four CRISPR gene editing therapies in small clinical studies, raised a $44.5 million Series B to test several more genetic medicines in humans and potentially ...